

Submission ID #: 68708

Scriptwriter Name: Sulakshana Karkala

Project Page Link: <https://review.jove.com/account/file-uploader?src=20955988>

Title: Microfluidics-Based High-Throughput Circulating Tumor Cell Sorting and Single-Cell Sequencing Technology

Authors and Affiliations:

Zheyu Liu^{1*}, Ye Tian^{3*}, Zian Zhang¹, Lingling Wu², Liang Dong¹, Wei Xue¹

¹Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

²Institute of Molecular Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

³Shanghai Jiao Tong University School of Medicine

***These authors contributed equally**

Corresponding Authors:

Liang Dong

drdongliang@126.com

Wei Xue

xuewei@renji.com

Email Addresses for All Authors:

Zheyu Liu

lzy02626@126.com

Ye Tian

late_fall@sjtu.edu.cn

Zian Zhang

zhang-zian@outlook.com

Lingling Wu

llwu@shsmu.edu.cn

Liang Dong

drdongliang@126.com

Wei Xue

xuewei@renji.com

Author Questionnaire

- 1. Microscopy:** Does your protocol require the use of a dissecting or stereomicroscope for performing a complex dissection, microinjection technique, or something similar? **No.**

- 2. Software:** Does the part of your protocol being filmed include step-by-step descriptions of software usage? **No.**

- 3. Filming location:** Will the filming need to take place in multiple locations? **No.**

Current Protocol Length

Number of Steps: 26

Number of Shots: 56

Introduction

Videographer: Obtain headshots for all authors available at the filming location.

- 1.1. **Zheyu Liu:** We focus on developing high-performance CTC isolation and analysis methods to advance precision oncology through liquid biopsy.

1.1.1. INTERVIEW: Named Talent says the statement above in an interview-style shot, looking slightly off-camera. *Suggested B.roll:2.6*

What are the current experimental challenges?

- 1.2. **Zheyu Liu:** Current commercial CTC isolation methods have low throughput and efficiency. They are also incompatible with downstream sequencing platforms, which limits biological information recovery.

1.2.1. INTERVIEW: Named Talent says the statement above in an interview-style shot, looking slightly off-camera.

What research gap are you addressing with your protocol?

- 1.3. **Zheyu Liu:** This study uses a microfluidic CTC isolation platform to greatly improve the detection rates. We also apply a rare-cell single-cell sequencing chip for deeper liquid biopsy analysis.

1.3.1. INTERVIEW: Named Talent says the statement above in an interview-style shot, looking slightly off-camera. *Suggested B.roll:3.8*

Videographer: Obtain headshots for all authors available at the filming location.

Protocol

2. Preparation of Immunomagnetic Beads and Initial HB-Chip Operation for Tumor Cell Isolation

Demonstrator: Zheyu Liu

- 2.1. To begin, pipette 25 microliters of washed and resuspended streptavidin-modified magnetic beads [1] into a tube containing 1 microgram of biotinylated EpCAM (*Epp-Cam*) antibody [2-TXT]. Incubate the mixture at room temperature while rotating at 20 revolutions per minute for 40 minutes to prepare the immunomagnetic beads [3].
 - 2.1.1. WIDE: Talent pipetting streptavidin-modified magnetic beads into a microcentrifuge tube.
 - 2.1.2. Talent pipetting EpCAM antibody into the tube. **TXT: EpCAM: Epithelial Cell Adhesion Molecule**
 - 2.1.3. Talent placing the tube on a rotator set to 20 revolutions per minute.
- 2.2. Using a magnetic rack, separate the beads from the supernatant [1]. After removing the supernatant, resuspend the beads in 25 microliters of isolation buffer [2-TXT].
 - 2.2.1. Talent placing the tube on a magnetic rack and allowing beads to collect at the side.
 - 2.2.2. Talent adding 25 μ L isolation buffer to the bead pellet and gently resuspending it. **TXT: Isolation Buffer: 1% BSA, 2 mM EDTA, D-PBS**
- 2.3. Pipette 20 microliters of the magnetic bead suspension within 1 to 2 seconds, ensuring no air bubbles are introduced [1]. Immediately place the chip vertically on a magnet and allow the beads to settle for 5 minutes without disturbance [2].
 - 2.3.1. Talent drawing 20 microliters of bead suspension into a pipette quickly, ensuring no bubbles form.
 - 2.3.2. Talent positioning the chip vertically against a magnet.
- 2.4. Collect 4 milliliters of the blood sample into a syringe, ensuring air bubbles are removed [1]. Seal the chip's inlet and outlet with liquid to eliminate air bubbles [2]. Then insert the sample inlet and outlet tubes into the chip [3].
 - 2.4.1. Talent drawing blood into a syringe while avoiding air bubbles.
 - 2.4.2. Talent sealing the chip's inlet and outlet with liquid. **NOTE: 2.4.2 and 2.4.3 are combined in one clip**

- 2.4.3. Talent connecting inlet and outlet tubing to the chip.
 - 2.5. Using a syringe pump, inject the sample at a flow rate of 1.5 milliliters per hour [1]. After loading the sample, inject 60 microliters of DPBS into the HB(H-B) -chip at a flow rate of 0.2 milliliters per hour to wash off unbound cells [2].
 - 2.5.1. Talent setting the syringe pump and starting the injection.
 - 2.5.2. Talent operating syringe pump to inject Dulbecco's phosphate-buffered saline at the set flow rate.
 - 2.6. Remove the magnet [1] and manually inject 1.5 milliliters of 5 percent BSA to wash the chip and release captured tumor cells [2].
 - 2.6.1. Talent removing magnet from the chip.
 - 2.6.2. Talent manually injecting bovine serum albumin solution into the chip.
3. **Microfluidic-based Circulating Tumor Cells (CTC) purification**
 - 3.1. Prepare a 10% MPTS (M-P-T-S) solution in ethanol [1-TXT]. Immediately introduce 20 microliters of the solution into the HB-chip and incubate at room temperature for 1 hour [2].
 - 3.1.1. Talent measuring and preparing (3-Mercaptopropyl) trimethoxysilane solution in ethanol. **TXT: MPTS: (3-Mercaptopropyl) trimethoxysilane**
 - 3.1.2. Talent pipetting 20 microliters of the solution into the HB-chip inlet.
 - 3.2. Rinse the HB-chip once with anhydrous ethanol [1]. Then dry it at 100 degrees Celsius for 1 hour [2].
 - 3.2.1. Talent using a pipette to rinse the chip with anhydrous ethanol.
 - 3.2.2. Talent placing the chip in a drying oven set to 100 degrees Celsius.
 - 3.3. Next, prepare GMBS (G-M-B-S) solution in ethanol at a concentration of 0.5 milligram per milliliter [1-TXT]. After cooling the chip to 37 degrees Celsius, introduce the GMBS solution and incubate [2-TXT].
 - 3.3.1. Talent preparing GMBS solution in a microcentrifuge tube. **TXT: GMBS: N-γ-maleimidobutyl-oxysuccinimide**
 - 3.3.2. Talent pipetting GMBS solution into the HB-chip inlet. **TXT: Incubation: RT, 30 min**
 - 3.4. Rinse the HB-chip two times with double-distilled water, followed by two rinses with DPBS [1]. Immediately add 15 micrograms per milliliter of streptavidin into the HB-chip and incubate at room temperature for 1 hour or overnight at 4 degrees Celsius [2].
 - 3.4.1. Talent the chip twice with double-distilled water and DPBS. **NOTE: step 3.4.1 and 3.4.2 are combined in one clip**
AUTHORS: Please perform one representative action

3.4.2. Talent pipetting streptavidin solution into the HB-chip inlet.

3.5. After incubation, rinse the HB-chip two times with DPBS saline [1].

3.5.1. Talent performing two Dulbecco's phosphate-buffered saline rinses on the chip.

3.6. Now, prepare the CD45 (*C-D-Forty-Five*) antibody buffer by adding 0.2 percent BSA (*B-S-A*) and 20 micrograms per milliliter biotinylated CD45 antibody to DPBS, and adjust to the final volume [1]. Inject 20 microliters of the CD45 antibody buffer into the HB-chip for negative selection of white blood cells [2]. After a 1-hour incubation at room temperature, rinse the chip with DPBS [3].

3.6.1. Talent preparing CD45 antibody buffer in a microcentrifuge tube.

3.6.2. Talent pipetting CD45 antibody buffer into the HB-chip inlet.

3.6.3. Talent rinsing the HB-chip with Dulbecco's phosphate-buffered saline.

3.7. Add a blocking solution containing 3 percent BSA and 0.05 percent Tween-20 into the HB-chip [1-TXT].

3.7.1. Talent pipetting blocking solution into HB-chip inlet. **TXT: Incubate and rinse with DPBS before sample loading**

3.8. Aspirate the prepared sample into a syringe, ensuring no air bubbles are present [1]. Then seal the chip's inlet and outlet with liquid [2], and connect inlet and outlet tubes to the chip [3].

3.8.1. Talent aspirating sample into syringe while avoiding air bubbles.

3.8.2. Talent sealing chip inlet and outlet with liquid.

3.8.3. Talent attaching inlet and outlet tubes to chip.

3.9. Using a syringe pump, inject the sample at a flow rate of 0.6 milliliters per hour [1]. Collect purified tumor cells from the chip outlet for counting and single-cell sequencing [2].

Talent setting and starting syringe pump for injection. **NOTE: step 3.9.1 and 3.9.2 are combined in one clip**

3.9.1. Talent collecting tumor cells from chip outlet into a microcentrifuge tube.

4. Circulating Tumor Cell Capture, Barcoded Bead Loading, and mRNA Preparation Using the HB-Chip

4.1. Pipette 200 microliters of 0.5 percent F-68 (*F-Sixty-Eight*) solution prepared in DPBS, into the chip inlet [1]. Perform water bath sonication while holding the chip [2]. When bubbles are visible across the microporous region, continue sonication for 30 seconds to remove bubbles from the dual wells [3].

4.1.1. Talent pipetting F-68 solution in Dulbecco's phosphate-buffered saline into chip inlet.

- 4.1.2. Talent submerging chip in water bath sonicator.
- 4.1.3. Close-up of bubbles across microporous region during sonication.
- 4.2. Next, inject 200 microliters of tumor cell suspension into the chip containing 60,000 dual wells [1-TXT].
 - 4.2.1. Talent pipetting tumor cell suspension into chip inlet. **TXT: Shake at 10 rpm/min, 5 min**
- 4.3. Gently pipette the cell suspension in the chip up and down twice [1], then place on a decolorizing shaker again at for 5 minutes to resuspend uncaptured cells and allow them to settle again [2]. Now add 200 microliters of DPBS and 0.5 percent F-68 solution through inlet and aspirate from outlet [3-TXT].
 - 4.3.1. Talent gently pipetting suspension inside chip.
 - 4.3.2. Talent placing chip back on decolorizing shaker.
 - 4.3.3. Talent adding wash solution through inlet and aspirating from outlet. **TXT: Repeat for a total of 3 washes**
- 4.4. After resuspending the barcoded bead suspension. Immediately inject 200 microliters of suspension into the chip inlet [1] and shake at 10 revolutions per minute for 20 seconds [2].
 - 4.4.1. Talent injecting resuspended beads into chip inlet.
 - 4.4.2. Talent placing the chip on a shaker set to 10 revolutions per minute.
- 4.5. Gently pipette bead suspension twice before placing it back on the shaker [1-TXT]
 - 4.5.1. Talent gently pipetting bead suspension in chip. **TXT: Repeat once**
- 4.6. Now withdraw barcoded bead suspension from outlet [1]. Then pipette 200 microliters of 20x Tris-EDTA (*Tris-E-D-T-A*) and 50 millimolar dithiothreitol solution [2]. Withdraw liquid from outlet [3-TXT].
 - 4.6.1. Talent withdrawing bead suspension from outlet.
 - 4.6.2. Talent adding Tris-EDTA and dithiothreitol solution into chip. **NOTE: step 4.6.2 and 4.6.3 are combined in one clip**
 - 4.6.3. Talent withdrawing solution from outlet. **TXT: Repeat wash for a total of 4 washes**
- 4.7. For cell lysis and mRNA (*M-R-N-A*) capture, slowly add 200 microliters of cell lysis buffer into the chip inlet [1]. Immediately add 200 microliters of mineral oil to seal the dual wells [2].
 - 4.7.1. Talent pipetting lysis buffer into chip inlet.
 - 4.7.2. Talent adding mineral oil immediately after lysis buffer.

- 4.8. Remove solution flowing from chip outlet into waste reservoir [1]. Then place the chip horizontally and let stand at room temperature for 5 minutes [2].
 - 4.8.1. Talent removing waste solution from outlet.
 - 4.8.2. Close-up of chip resting horizontally on bench.
- 4.9. Slowly add 200 microliters of 6x saline-sodium citrate solution into inlet [1]. Remove the waste liquid and aspirate the remaining solution from chip outlet [2].
 - 4.9.1. Talent adding saline-sodium citrate solution into chip inlet. **NOTE: step 4.9.1 and 4.9.2 are combined in one clip**
 - 4.9.2. Talent removing waste solution from outlet and pipetting out the remaining solution from chip outlet.
- 4.10. Slowly add 200 microliters of 6x saline-sodium citrate to fill chip [1]. Hold a magnet near chip surface and move it slowly from inlet to outlet to gather barcoded beads [2]. Quickly aspirate solution and beads into a centrifuge tube containing 6x saline-sodium citrate [3].
 - 4.10.1. Talent filling chip with saline-sodium citrate.
 - 4.10.2. Close-up of magnet being moved along chip surface.
 - 4.10.3. Talent aspirating bead-containing solution into centrifuge tube.
- 4.11. Wash the barcoded beads three times with 200 microliters of 6x saline-sodium citrate [1], followed by once with reverse transcription buffer [2].
 - 4.11.1. Talent washing beads with saline-sodium citrate. **TXT: Repeat for a total of 3 washes**
 - 4.11.2. Talent washing beads once with reverse transcription buffer.

Results

5. Results

- 5.1. A uniform distribution of immunomagnetic beads was observed under a magnetic field [1], while minimal residual beads after magnetic removal confirmed successful release [2].
 - 5.1.1. LAB MEDIA: Figure 2C. *Video editor: please highlight the top image*
 - 5.1.2. LAB MEDIA: Figure 2C. *Video editor: please highlight the bottom image.*
- 5.2. The CTC (C-T-C) isolation chip efficiently captured tumor cells from both 1 milliliter and 10 milliliter samples [1-TXT]. The addition of the purification chip further increased tumor cell purity [2].
 - 5.2.1. LAB MEDIA: Figure 2D.
TXT: CTC: Circulating Tumor Cell
Video editor: Please highlight the 1mL and 10 mL bars
 - 5.2.2. LAB MEDIA: Figure 2E. *Video editor: Highlight the bars in the “Both” group*
- 5.3. In peripheral blood samples spiked with minimal LNCaP (Lin-Cap) cells [1], the CTC sorting system maintained high capture efficiency and purity [2].
 - 5.3.1. LAB MEDIA: Figure 2F. *Video editor: Highlight the green fluorescent cells in the “LNCaP-Calcein AM” panel.*
 - 5.3.2. LAB MEDIA: Figure 2G. *Video editor: Highlight both the red bars and blue dots in the “1 mL” and “10 mL” groups.*
- 5.4. The single-cell barcoding chip achieved an 85.6% cell [1] and 95.7% barcoded bead occupancy ratio [2], resulting in a pairing rate of 81.9% [3].
 - 5.4.1. LAB MEDIA: Figure 3D (left). *Video editor: Please highlight the red bar labeled “Cell”*
 - 5.4.2. LAB MEDIA: Figure 3D (left). *Video editor: Highlight the blue bar labeled “Bead”*
 - 5.4.3. LAB MEDIA: Figure 3D (left). *Video editor: Highlight the green bar labeled “Pairing”*
- 5.5. Increasing the number of loaded cells improved the microwell occupancy ratio [1] without reducing capture efficiency [2].
 - 5.5.1. LAB MEDIA: Figure 3C. *Video editor: Highlight the blue line increasing toward the right side of the graph.*

- 5.5.2. LAB MEDIA: Figure 3C. *Video editor: Highlight the flat red line across the graph.*
- 5.6. The integrated CTC isolation and single-cell sequencing workflow produced highly pure tumor cells [1] and accurately retained the original tumor cell ratios [2]. t-SNE (*T-S-N-E*) analysis distinctly separated PC3(*P-C-Three*), LNCaP, and Jurkat cells into three clusters, each characterized by unique marker expression [3].
- 5.6.1. LAB MEDIA: Figure 4B. *Video editor: Highlight the large yellow and blue sections in the “Purified” bar.*
- 5.6.2. LAB MEDIA: Figure 4B. *Video editor: Highlight the yellow and blue in “Purified” and “Output” bars.*
- 5.6.3. LAB MEDIA: Figure 4A. *Video editor: Highlight the three distinct color clusters.*
- 5.7. The Jurkat cell cluster was identified by strong expression of TRBC1(*T-R-B-C-One*), IGLL1 (*Eye-G-L-L-One*), CD1E(*C-D-One-E*), and CD3D (*C-D-Three-D*) [1], confirmed by pathway enrichment for T cell activation [2].
- 5.7.1. LAB MEDIA: Figure 4D. *Video editor: Highlight the TRBC1, CD3D and CD1E marker plots*
- 5.7.2. LAB MEDIA: Figure 4E. *Video editor: Highlight the “alpha-beta T cell activation” and “T cell differentiation” boxes.*
- 5.8. PC3 and LNCaP clusters were distinguished by differentially expressed genes, with PC3 showing high microseminoprotein expression [1] and LNCaP expressing NEDD4 (*Ned-Four*) [2].
- 5.8.1. LAB MEDIA: Figure 4F–G. *Video editor: Highlight the the MSMP plot in 4F*
- 5.8.2. LAB MEDIA: Figure 4F–G. *Video editor: Highlight the NEDD4 plot in 4F*

- **Streptavidin**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/streptavidin>

IPA: /strep'tævɪdɪn/

Phonetic Spelling: strep-ta-vi-din

- **Biotinylated**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/biotinylated>

IPA: /ˌbaɪoʊˈtɪnɪleɪtɪd/

Phonetic Spelling: bye-oh-tin-uh-lay-tid

- **EpCAM (Epithelial Cell Adhesion Molecule)**

No confirmed link found

IPA: /'ɛpkæm/

Phonetic Spelling: Epp-Cam

- **Supernatant**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/supernatant>

IPA: /'su:pərˌneɪtənt/

Phonetic Spelling: soo-per-nay-tent

- **BSA (Bovine Serum Albumin)**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/albumin>

IPA: /'boʊvənˈsɪrəmˈælbjʊmɪn/

Phonetic Spelling: boh-vine seer-um al-byoo-min

- **EDTA (Ethylenediaminetetraacetic acid)**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/EDTA>

IPA: /ˌiːdiːtiːˈeɪ/

Phonetic Spelling: E-D-T-A

- **DPBS (Dulbecco's Phosphate-Buffered Saline)**

No confirmed link found

IPA: /ˌdiːpiːbiːˈes/

Phonetic Spelling: D-P-B-S

- **MPTS (3-Mercaptopropyl trimethoxysilane)**

No confirmed link found

IPA: /ɛm-piː-tiː-ɛs/

Phonetic Spelling: M-P-T-S

- **Anhydrous**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/anhydrous>

IPA: /ænˈhaɪdrəs/

Phonetic Spelling: an-hy-drus

- **GMBS (N-γ-maleimidobutyl-oxysuccinimide)**

No confirmed link found

IPA: /dʒiː-ɛm-biː-ɛs/

Phonetic Spelling: G-M-B-S

- **Streptavidin** (repeated, already above in #3)
- **CD45**
No confirmed link found
IPA: /,siːˌdiːˈfɔrti faɪv/
Phonetic Spelling: C-D-Forty-Five
- **Tween-20**
No confirmed link found
IPA: /twiːnˈtwenti/
Phonetic Spelling: tween-twenty
- **F-68 (Pluronic F-68)**
No confirmed link found
IPA: /ɛfˌsɪkstiˈeɪt/
Phonetic Spelling: F-Sixty-Eight
- **Microporous**
Pronunciation link:
<https://www.merriam-webster.com/dictionary/microporous>
IPA: /ˌmaɪkroʊˈpɒrəs/
Phonetic Spelling: my-kroh-por-us
- **Tris-EDTA**
No confirmed link found
IPA: /ˌtrɪs ˌɪːdiːtiːˈeɪ/
Phonetic Spelling: tris-E-D-T-A
- **Dithiothreitol (DTT)**
Pronunciation link:
<https://www.merriam-webster.com/dictionary/dithiothreitol>
IPA: /daɪˌθaɪoʊˈθriːl ˌtɔl/
Phonetic Spelling: dye-thy-oh-three-ee-tawl
- **mRNA**
Pronunciation link:
<https://www.merriam-webster.com/dictionary/mRNA>
IPA: /ˌɛmˌɑrənˈeɪ/
Phonetic Spelling: M-R-N-A
- **Saline-sodium citrate**
No confirmed link found
IPA: /ˈseɪˌlɪn ˈsoʊdiəm ˈsaɪtreɪt/
Phonetic Spelling: say-leen so-dee-um sy-trayt

- **Reverse Transcription**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/reverse%20transcription>

IPA: /rɪˈvɜrs trænˈskrɪpʃən/

Phonetic Spelling: ree-vurs tran-skrip-shun

- **CTC (Circulating Tumor Cell)**

No confirmed link found

IPA: /ˌsiːtiːˈsiː/

Phonetic Spelling: C-T-C

- **LNCaP**

No confirmed link found

IPA: /ˈlɪnˌkæp/

Phonetic Spelling: Lin-Cap

- **t-SNE (t-distributed stochastic neighbor embedding)**

No confirmed link found

IPA: /tiː-ɛs-ɛnˈiː/

Phonetic Spelling: T-S-N-E

- **PC3**

No confirmed link found

IPA: /piː-siː-θriː/

Phonetic Spelling: P-C-Three

- **Jurkat**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/Jurkat>

IPA: /ˈdʒɜrkæt/

Phonetic Spelling: jur-kat

- **TRBC1**

No confirmed link found

IPA: /tiː-ɑr-biː-siː-wʌn/

Phonetic Spelling: T-R-B-C-One

- **IGLL1**

No confirmed link found

IPA: /aɪ-dʒiː-ɛl-ɛl-wʌn/

Phonetic Spelling: Eye-G-L-L-One

- **CD1E**

No confirmed link found

IPA: /si:-di:-wʌn-i:/

Phonetic Spelling: C-D-One-E

- **CD3D**

No confirmed link found

IPA: /si:-di:-three-di:/

Phonetic Spelling: C-D-Three-D

- **NEDD4**

No confirmed link found

IPA: /nɛd-fɔr/

Phonetic Spelling: Ned-Four

- **Microseminoprotein (MSMP)**

Pronunciation link:

<https://www.merriam-webster.com/dictionary/microseminoprotein>

IPA: /,maɪkroʊˌseminooˈproʊtɪn/

Phonetic Spelling: my-kroh-sem-ih-no-pro-teen